1. Agonist antibody to MuSK protects mice from MuSK myasthenia gravis.
- Author
-
Oury J, Gamallo-Lana B, Santana L, Steyaert C, Vergoossen DLE, Mar AC, Vankerckhoven B, Silence K, Vanhauwaert R, Huijbers MG, and Burden SJ
- Subjects
- Animals, Mice, Humans, LDL-Receptor Related Proteins immunology, Autoantibodies immunology, Female, Myasthenia Gravis, Autoimmune, Experimental immunology, Myasthenia Gravis, Autoimmune, Experimental drug therapy, Antibodies immunology, Antibodies pharmacology, Disease Models, Animal, Fatty Acids, Monounsaturated, Receptor Protein-Tyrosine Kinases immunology, Receptor Protein-Tyrosine Kinases metabolism, Neuromuscular Junction drug effects, Neuromuscular Junction immunology, Receptors, Cholinergic immunology, Receptors, Cholinergic metabolism, Myasthenia Gravis immunology, Myasthenia Gravis drug therapy
- Abstract
Myasthenia gravis (MG) is a chronic and severe disease of the skeletal neuromuscular junction (NMJ) in which the effects of neurotransmitters are attenuated, leading to muscle weakness. In the most common forms of autoimmune MG, antibodies attack components of the postsynaptic membrane, including the acetylcholine receptor (AChR) or muscle-specific kinase (MuSK). MuSK, a master regulator of NMJ development, associates with the low-density lipoprotein-related receptor 4 (Lrp4) to form the signaling receptor for neuronal Agrin, a nerve-derived synaptic organizer. Pathogenic antibodies to MuSK interfere with binding between MuSK and Lrp4, inhibiting the differentiation and maintenance of the NMJ. MuSK MG can be debilitating and refractory to treatments that are effective for AChR MG. We show here that recombinant antibodies, derived from MuSK MG patients, cause severe neuromuscular disease in mice. The disease can be prevented by a MuSK agonist antibody, presented either prophylactically or after disease onset. These findings suggest a therapeutic alternative to generalized immunosuppression for treating MuSK MG by selectively and directly targeting the disease mechanism., Competing Interests: Competing interests statement:C.S., B.V., K.S., and R.V. are employees of and have equity ownership in argenx BV. Issued patents: S.J.B., NYU Medical School, US9329182 S.J.B., Wei Zhang, Maartje Huijbers, Johannes J. Verschuuren, and Silvere M. van der Maarel; NYU Medical School and LUMC; US20150125442A1 S.J.B. et al., NYU Medical School and argenx; US11492401 Patent applications: M.G.H. et al., LUMC, WO2020/055241 M.G.H. et al., LUMC and argenx, WO2021/180676 R.V. et al.; argenx, Université de Montréal and NYU Medical School; WO2023/147489 R.V. et al.; argenx and NYU Medical School; WO2023/218099. S.J.B. is grateful for financial support for research from argenx.
- Published
- 2024
- Full Text
- View/download PDF